Serina Therapeutics awarded patent for its core polymer drug delivery technology

Huntsville, AL, May 17, 2011

Serina Therapeutics, Inc., a pharmaceutical research and development company, announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology. The patent entitled “Polyoxazoline and compositions comprising the same” (U.S. Patent No. 7,943,141) covers the synthesis and composition of polyoxazolines for the delivery of different drug molecules.

The patent represents years of groundbreaking research in the development of safe polyoxazoline polymers for drug delivery. It is the first of many patents that Serina has applied for. “This patent award validates our invention and design of a novel drug delivery platform and allows Serina the opportunity to advance some of its proprietary ideas towards full development and eventually commercialization”, said Dr. Michael D. Bentley, Chief Scientific Officer and cofounder of the company. “We are now in a position to build a strong pipeline of polymer therapeutic molecules”.

About Serina

Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com